Real-World Phlebotomy Burden and Treatment Gaps in United States Patients With Polycythemia Vera: A Chart Review Across Physician Practice Settings (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-572; Location: LEVEL 3, HALL B3; "At the time of management change from phlebotomy, 47% were receiving concurrent CRT, whereas 45% initiated a new CRT thereafter (most commonly hydroxyurea [42%], ruxolitinib [36%], and ropeginterferon alfa-2b [21%]), and 15% did not receive CRT. Phlebotomy remains widely used in PV care but is associated with substantial procedural burden and frequent management changes. Reporting of inadequate hematocrit control as a driver of management change, treatment-related ID, fatigue, and continued need for management changes despite concurrent CRT collectively point to an urgent need for more effective, better-tolerated treatments."
Clinical • Real-world • Real-world evidence • Review • Oncology • Polycythemia Vera
|
|
Andrew Srisuwananukorn MD 1; Angela (Qi) Fan MPH 2; Alicia Cerretani PharmD 3; Swapna Munnangi PhD 4; Grace Gahlon PhD 4; Shelby Corman PharmD 4; Luis Hernandez PhD 2; Naveen Pemmaraju MD 5
|